November 01, 1997; 49 (5 Suppl 4) Articles
Antiplatelet drugs in secondary prevention of stroke
Lessons from recent trials
Hans-Christoph Diener
First published November 1, 1997, DOI: https://doi.org/10.1212/WNL.49.5_Suppl_4.S75
Hans-Christoph Diener
MD
Antiplatelet drugs in secondary prevention of stroke
Lessons from recent trials
Hans-Christoph Diener
Neurology Nov 1997, 49 (5 Suppl 4) S75-S81; DOI: 10.1212/WNL.49.5_Suppl_4.S75
Citation Manager Formats
Make Comment
See Comments

Article Information
vol. 49 no. 5 Suppl 4 S75-S81
PubMed:
Print ISSN:
Online ISSN:
History:
- First Published November 1, 1997.
Copyright & Usage:
© 1997
Author Disclosures
- Hans-Christoph Diener, MD
- Hans-Christoph Diener, MD
- From the Department of Neurology, University of Essen, Germany.
- Address correspondence and reprint requests to Dr. Hans-Christoph Diener, Department of Neurology, University of Essen, D-45122 Essen, Germany.
Article usage
Cited By...
Letters: Rapid online correspondence
No comments have been published for this article.
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Advertisement
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Review
Selecting an Optimal Antiplatelet Agent for Secondary Stroke PreventionKaren C. Albright, Virginia J. Howard, George Howard et al.Neurology: Clinical Practice, May 06, 2020 -
Article
Early time course of major bleeding on antiplatelet therapy after TIA or ischemic strokeNina A. Hilkens, Ale Algra, L. Jaap Kappelle et al.Neurology, January 26, 2018 -
Views & Reviews
Choice of endpoints in antiplatelet trialsWhich outcomes are most relevant to stroke patients?Gregory W. Albers et al.Neurology, March 14, 2000 -
Article
Lp-PLA2 and dual antiplatelet agents in intracranial arterial stenosisMing Yang, Anxin Wang, Jiejie Li et al.Neurology, December 10, 2019